13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001335325
Total reported value
$438.6M
$438.6M
145 檔
16.0%
According to the latest 13F quarterly dataset, HighVista Strategies LLC managed an equity portfolio of $438.6M at the end of Q4 2025, spanning 145 distinct U.S. exchange-listed positions.
In Q4 2025, HighVista Strategies LLC adopted a defensive or profit-taking posture, trimming 86 positions and completely liquidating 36 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DBC | Invesco Db Commodity Index T | ETF-Commodities | 6.09% | -2.02% | -26.38% | |
| 2 | GPCR | Structure Therapeutics Inc | Stock-Other | 3.46% | -0.05% | -18.30% | |
| 3 | COGT | Cogent Biosciences Inc | Stock-Other | 3.08% | -0.42% | -27.19% | |
| 4 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.99% | -0.05% | -20.64% | |
| 5 | ABVX | Abivax Sa-adr | Stock-Other | 2.51% | -0.05% | -60.87% | |
| 6 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.47% | +1.00% | -31.47% | |
| 7 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.96% | -0.03% | -72.80% | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 1.90% | -1.60% | EXIT | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.87% | +0.45% | -13.82% | |
| 10 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.83% | -1.66% | EXIT | |
| 11 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.82% | +0.11% | — | |
| 12 | INSM | Insmed Inc | Stock-Healthcare | 1.77% | -0.34% | -21.12% | |
| 13 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.73% | -0.83% | EXIT | |
| 14 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.65% | -0.31% | -39.56% | |
| 15 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.61% | -1.53% | EXIT | |
| 16 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.59% | -0.47% | -12.77% | |
| 17 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.58% | -0.80% | -2.14% | |
| 18 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.55% | -0.02% | -44.76% | |
| 19 | IMVT | Immunovant Inc | Stock-Other | 1.45% | +0.90% | -12.34% | |
| 20 | LQDA | Liquidia CORP | Stock-Other | 1.39% | +0.74% | -11.61% | |
| 21 | PCVX | Vaxcyte Inc | Stock-Other | 1.36% | -0.02% | +31.39% | |
| 22 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.30% | — | -67.66% | |
| 23 | ACLXGBX | Arcellx Inc | Stock-Other | 1.26% | — | -22.02% | |
| 24 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.19% | +1.00% | +126.68% | |
| 25 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.18% | -0.05% | +14.37% | |
| 26 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.16% | +0.18% | -40.65% | |
| 27 | PHVS | Pharvaris N.V. | Stock-Other | 1.16% | +0.51% | — | |
| 28 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.13% | +0.23% | +115.51% | |
| 29 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.09% | +0.04% | -17.76% | |
| 30 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.08% | -0.12% | +222.73% | |
| 31 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.04% | — | -24.39% | |
| 32 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 1.03% | -0.56% | -34.08% | |
| 33 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 0.98% | — | +3.46% | |
| 34 | GH | Guardant Health Inc | Stock-Healthcare | 0.97% | -0.07% | -43.08% | |
| 35 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.94% | -0.10% | — | |
| 36 | CMPS | Compass Pathways PLC | Stock-Other | 0.89% | +0.64% | — | |
| 37 | MSFT | Microsoft CORP | Stock-Tech | 0.81% | -0.45% | -30.88% | |
| 38 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 0.80% | +0.39% | — | |
| 39 | PALI | Palisade Bio Inc | Stock-Other | 0.79% | -0.01% | — | |
| 40 | GHRS | GH Research PLC | Stock-Other | 0.79% | +0.14% | -0.57% | |
| 41 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.78% | -0.03% | -11.80% | |
| 42 | XOMA | Xoma Royalty Corporation | Stock-Other | 0.77% | -0.41% | EXIT | |
| 43 | TDG | Transdigm Group Inc | Stock-Industrials | 0.74% | -0.07% | — | |
| 44 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.74% | — | -38.98% | |
| 45 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.74% | +0.23% | — | |
| 46 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.74% | -0.19% | EXIT | |
| 47 | NVDA | Nvidia CORP | Stock-Tech | 0.68% | -0.09% | +6.12% | |
| 48 | CRM | Salesforce Inc | Stock-Tech | 0.59% | -0.43% | EXIT | |
| 49 | V | Visa Inc-class A Shares | Stock-Financials | 0.57% | -0.13% | -19.97% | |
| 50 | SEPN | Septerna Inc | Stock-Other | 0.56% | +0.22% | NEW |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GPCR | Structure Therapeutics Inc | +1.8% | -18.30% | Trim |
| 2 | COGT | Cogent Biosciences Inc | +1.5% | -27.19% | Trim |
| 3 | SLNOEUR | Soleno Therapeutics Inc | +1.3% | +622.29% | Add |
| 4 | RLAY | Relay Therapeutics Inc | +0.9% | +126.68% | Add |
| 5 | OCUL | Ocular Therapeutix Inc | +0.8% | +222.73% | Add |
| 6 | TARS | Tarsus Pharmaceuticals Inc | +0.8% | +115.51% | Add |
| 7 | PRAX | Praxis Precision Medicines I | +0.7% | -72.80% | Trim |
| 8 | SYRE | Spyre Therapeutics Inc | +0.7% | -12.77% | Trim |
| 9 | APGE | Apogee Therapeutics Inc | +0.7% | -16.69% | Trim |
| 10 | PCVX | Vaxcyte Inc | +0.6% | +31.39% | Add |
| 11 | BBIO | Bridgebio Pharma Inc | +0.5% | -2.14% | Trim |
| 12 | VRDN | Viridian Therapeutics Inc | +0.5% | -20.64% | Trim |
| 13 | OLMA | Olema Pharmaceuticals Inc | +0.5% | -44.76% | Trim |
| 14 | RVMD | Revolution Medicines Inc | +0.5% | -31.47% | Trim |
| 15 | IMVT | Immunovant Inc | +0.5% | -12.34% | Trim |
| 16 | LQDA | Liquidia CORP | +0.4% | -11.61% | Trim |
| 17 | AVTX | Avalo Therapeutics Inc | +0.4% | +244.27% | Add |
| 18 | EWTX | Edgewise Therapeutics Inc | +0.3% | -17.76% | Trim |
| 19 | CELC | Celcuity Inc | +0.3% | +20.93% | Add |
| 20 | RYTM | Rhythm Pharmaceuticals Inc | +0.3% | +14.37% | Add |
| 21 | AXSM | Axsome Therapeutics Inc | +0.2% | +19.07% | Add |
| 22 | APLSUSD | Apellis Pharmaceuticals Inc | +0.2% | +3.46% | Add |
| 23 | BKNG | Booking Holdings Inc | +0.1% | +54.78% | Add |
| 24 | NEE | Nextera Energy Inc | +0.1% | +22.43% | Add |
| 25 | NAMS | NewAmsterdam Pharma Company N.V. | +0.1% | +11.80% | Add |
| 26 | CYTK | Cytokinetics Inc | +0.1% | -13.82% | Trim |
| 27 | NVDA | Nvidia CORP | +0.1% | +6.12% | Add |
| 28 | ALC | Alcon Inc. | +0.1% | +32.79% | Add |
| 29 | CGON | Cg Oncology Inc | +0.1% | +12.62% | Add |
| 30 | GEV | GE Vernova Inc | +0.1% | +7.15% | Add |
| 31 | RNAGBP | Avidity Biosciences Inc | 0% | -38.98% | Trim |
| 32 | ARGX | Argenx Se - Adr | 0% | -11.80% | Trim |
| 33 | AFRM | Affirm Holdings Inc | 0% | +4.69% | Add |
| 34 | ETR | Entergy CORP | 0% | +7.58% | Add |
| 35 | MDGL | Madrigal Pharmaceuticals Inc | 0% | -19.73% | Trim |
| 36 | TCOM | Trip.com Group Ltd-adr | 0% | +9.12% | Add |
| 37 | INSM | Insmed Inc | 0% | -21.12% | Trim |
| 38 | SE | Sea Ltd-adr | 0% | +44.91% | Add |
| 39 | URGN | UroGen Pharma Ltd. | 0% | -12.17% | Trim |
| 40 | CTMX | Cytomx Therapeutics Inc | 0% | -24.58% | Trim |
| 41 | PFSI | Pennymac Financial Services | 0% | -6.37% | Trim |
| 42 | TYRA | Tyra Biosciences Inc | 0% | -46.69% | Trim |
| 43 | RXO | Rxo Inc | — | +12.41% | Add |
| 44 | OFIX | Orthofix Medical Inc | — | -8.75% | Trim |
| 45 | BZ | Kanzhun LTD - Adr | — | +8.98% | Add |
| 46 | NOK | Nokia Corp-spon Adr | — | -28.20% | Trim |
| 47 | DNTH | Dianthus Therapeutics Inc | 0% | -10.59% | Trim |
| 48 | GH | Guardant Health Inc | 0% | -43.08% | Trim |
| 49 | RBC | RBC Bearings Inc | 0% | -22.77% | Trim |
| 50 | FOUR | Shift4 Payments Inc-class A | 0% | +3.86% | Add |
According to official SEC Form 13F filings, HighVista Strategies LLC reported a total U.S. public equity portfolio value of $438.6M across 145 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DBC, GPCR, COGT) accounted for 16.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
430
市值: $7.1M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $12.6M
During Q4 2025, HighVista Strategies LLC's top holdings by market value included DBC (6.1%)、GPCR (3.5%)、COGT (3.1%). The largest single position, DBC, represented 6.1% of total portfolio value.
In Q4 2025, HighVista Strategies LLC made 181 total portfolio adjustments, initiating 33 new buys, adding to 26 positions, trimming 86 holdings, and fully liquidating 36 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.